Abaco Capital plc

 

Investor Relations

Board of Directors

David Norwood, Chairman

David Norwood is a founding shareholder in Oxford Pharmascience. David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses and a shareholder in the Company.

Previously, he was Chief Executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (recently acquired by Investec), and also co-founder of Ora Capital plc. David has been a founder and/or director of many UK technology companies including Oxford Nanopore, Proximagen, Synairgen, Ilika, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy).

He has also acted as seed investor and/or advisor to Wolfson Microelectronics, Nanoco, Tissue Regenix and Arc International (now part of Synopsys). He is also Chairman of Retroscreen Virology Limited, Europe's leading specialist virology contract research organisation.

Chris Hill, Chief Financial Officer

Chris Hill graduated in Economics and Public Policy in 2001 from Leeds Metropolitan University where he combined his studies with a professional rugby career. He then went on to gain his chartered accountancy qualification with Grant Thornton UK LLP. Before becoming CFO at Oxford Pharmascience Group plc, Chris was Group Financial Controller of ORA Capital Partners plc, an early stage investor in UK growth companies. Chris is also a director of Quoram Plc and Oxford Advanced Surfaces Ltd.

John Goddard, Non-Executive Director

John Goddard has had a distinguished career in the global pharmaceutical industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning and Business Development. Prior to his retirement from AstraZeneca in 2010, he was responsible for a 100 strong global team focused on M&A and licensing, which completed around 75 transactions in four years including several acquisitions, in-licensing and out-licensing of compounds and disposals. Latterly, Mr. Goddard became Chairman of two AstraZeneca subsidiaries, Aptium Oncology in the US and Astratech in Sweden. He is currently a member of the Board of Directors of Optos PLC and IntasPharmaceuticals Limited. Mr Goddard is a Fellow of the Institute of Chartered Accountants and a Member of the Association of Corporate Treasurers.